AI-ECG Platform vs FibriCheck
AI Verdict
Choose AI-ECG Platform if…
Choose the AI-ECG Platform if your clinical setting requires rapid, highly accurate AI-assisted interpretation of standard 12-lead resting ECGs. This tool is ideal for physicians in cardiology, emergency medicine, or internal medicine who need to diagnose a broad spectrum of cardiovascular diseases, including arrhythmias, myocardial ischemia, and infarction, with over 95% accuracy. Its hardware independence and professional diagnostic client make it suitable for integration into existing clinical workflows for definitive in-clinic diagnosis.
View AI-ECG Platform →Choose FibriCheck if…
Choose FibriCheck if you need a solution for remote patient monitoring, enabling individuals to regularly check their heart rhythm using just a smartphone camera. This app is particularly well-suited for detecting and monitoring arrhythmias like Atrial Fibrillation (AFib) outside of a clinical setting, providing immediate, actionable results for patients and a dedicated portal for healthcare providers to oversee and manage patient data with customizable monitoring rules.
View FibriCheck →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AI-ECG Platform | FibriCheck |
|---|---|---|
| Pricing | Unknown | Subscription-based, with options for monthly or annual payments. prices vary by region and may be partly or fully covered by insurance or employer. |
| Deployment | On-premise (AI-ECG Workstation), web-based (Management Portal), and client-based (AI-ECG Diagnostic Client). | Cloud-based (private cloud). |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
FibriCheckFibriCheck (Tool B) offers superior usability due to its smartphone-based, patient-facing application, making heart rhythm monitoring highly accessible for end-users. Its direct integration with a device most people already own simplifies the user experience significantly. While Tool A provides a web portal and client, Tool B's approach caters to a broader audience with minimal setup.
Clinical Value
AI-ECG PlatformThe AI-ECG Platform (Tool A) demonstrates broader clinical value by providing comprehensive AI-powered analysis of 12-lead resting ECGs, diagnosing a wider range of conditions including arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction with over 95% accuracy. This directly assists physicians in interpreting standard clinical data for critical diagnoses. FibriCheck (Tool B) focuses primarily on arrhythmia detection and monitoring via smartphone PPG, which, while valuable, has a narrower diagnostic scope compared to a full 12-lead ECG interpretation.
Pricing & Value
FibriCheckFibriCheck (Tool B) offers transparent and clearly stated pricing for end-users through monthly/yearly subscriptions and specific rates for doctor-prescribed use, allowing for easy assessment of its value proposition. In contrast, the AI-ECG Platform (Tool A) requires direct contact for pricing, making it difficult for potential users to understand the cost and value without an initial inquiry.
Enterprise Readiness
AI-ECG PlatformThe AI-ECG Platform (Tool A) exhibits stronger enterprise readiness with its support for various standard ECG data formats (HL7 aECG, DICOM ECG, SCP ECG, MFER ECG) and a dedicated Web-based Management Portal for organization settings, security, and task management. These features facilitate seamless integration into existing clinical workflows and IT infrastructure. While FibriCheck (Tool B) has a healthcare professional portal, Tool A's explicit focus on interoperability with diverse ECG systems and robust management capabilities gives it an edge for large-scale clinical deployments.
Innovation
FibriCheckFibriCheck (Tool B) demonstrates greater innovation by utilizing smartphone camera-based PPG technology for heart rhythm measurement, enabling accessible and convenient patient self-monitoring outside traditional clinical settings. This approach represents a disruptive shift in how cardiac care can be delivered directly to consumers. While Tool A innovatively applies AI to traditional 12-lead ECG interpretation, Tool B's novel use of ubiquitous technology for remote monitoring is more transformative.
Support & Docs
FibriCheckFibriCheck (Tool B) provides more accessible and explicit support resources, including a 'Help Center' with FAQs and user guides, which is typical for a patient-facing application. While Shenzhen Carewell Electronics (Tool A's company) mentions general technical support, specific documentation or a dedicated support portal for the AI-ECG Platform is not readily available or detailed. This transparency in support resources gives Tool B an advantage.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AI-ECG Platform | FibriCheck |
|---|---|---|
| Name | AI-ECG Platform | FibriCheck |
| Company | Shenzhen Carewell Electronics Co., Ltd. | Qompium nv |
| Primary Technology/Method | AI automatic analysis and diagnosis system for 12-lead resting ECGs | Smartphone camera-based PPG technology for heart rhythm measurement |
| Key Detections/Diagnoses | Arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction | Atrial Fibrillation (AFib) and other arrhythmias |
| Target User | Physicians | Patients (with healthcare professional portal/dashboard for monitoring) |
Videos
Demos, reviews, and walkthroughs featuring AI-ECG Platform and FibriCheck.